HALLE, Germany--(BUSINESS WIRE)-- Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply agreement with Actavis, one of the world's leading generic pharmaceutical companies, for the future manufacturing of Reteplase. Financial terms were not disclosed.
Reteplase is a recombinant protein and the active ingredient in the medicinal product Rapilysin® for thrombolytic treatment of myocardial infarction. Scil Proteins originally signed an agreement with Roche in June 2008 for process transfer and manufacture of Reteplase. The protein was the first biologic which was invented, developed and produced in Germany. It has a demanding production process requiring considerable experience in protein refolding that only Scil Proteins could deliver. Actavis owns rights on the Reteplase production process and on Rapilysin® for European and worldwide distribution excluding USA and Canada.
“We are extremely happy to be working for one of the world’s leading players in first-class generic pharmaceuticals” commented Dr. Ulrike Fiedler, CEO of Scil Proteins. “This product has a complex production process but one that we have considerable experience in.”
As well as the previous agreement with Roche, this new agreement with Actavis adds to Scil Proteins’ portfolio of contract development and manufacturing clients. Previous customers have included global pharma companies such as Pfizer, Novartis, Sanofi, Lundbeck, large biotech companies such as Austria-based Intercell as well as numerous small biotech companies.
- Ends -
Notes to Editors
About Scil Proteins
Scil Proteins is a biopharmaceutical company working with industry partners in the development and manufacture of protein therapeutics and diagnostics as well as discovering and developing proprietary Affilin® molecules. The company has a longstanding expertise in protein production and development and offers GMP contract biomanufacturing and process development to biotech and pharma companies. With state of the art equipment and a particular expertise at refolding proteins, Scil Proteins has an excellent track record in supplying a top level support for its partners. Scil Proteins has supported a number of different pharma and biotech companies in process development and biomanufacturing. Scil Proteins also has a discovery platform that is a fully patent protected screening technology for the identification of target-specific Affilin® molecules using advanced selection systems. Affilin® molecules are therapeutics and diagnostics based on a scaffold derived from the human protein Ubiquitin to form highly stable molecules with strong binding specificity and low immunogenicity. Scil Proteins has generated a pipeline of Affilin® therapeutics targeting cancer. Scil Proteins is a well-established private company located in Halle, Germany. To learn more about Scil Proteins, please visit www.scilproteins.com.
About Actavis Group
Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. The company has operations in 40 countries, with 10,000 employees. For further information on Actavis Group, please visit www.actavis.com.
CONTACT:
Scil Proteins
Dr. Ulrike Fiedler
CEO
t: +49 (0) 345 27 99 63 30
e: [email protected]
or
College Hill Life Sciences
Dr. Robert Mayer - Account Director
Lauren McConville - Account Manager
t: +49 (0) 89 52 05 92 12
e: [email protected]
KEYWORDS: Europe Germany
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical
MEDIA:
| Logo |